Back to the Top
Hello,
Is any data or literature available citing the presence of drug
metabolizing enzymes in skin that may be responsible for drug
metabolism after transdermal patch application? I vaguely remember
some reference to skin esterases but I am more interested in CYP
enzymes.
This leads to the next question. Is it OK to assume complete
bioavailability when developing PK models for drug disposition after
patch application? (Of course, residual drug in the patch and any
volatile drug loss will be accounted for in dose calculation)
Kindly advice,
Mahesh
Back to the Top
The following message was posted to: PharmPK
Dear Mahesh,
Please find here a recent paper
Pharmaceutical Research, Vol. 22, No. 6, June 2005 (# 2005) pp842-846
Regars
Mathy Francois-Xavier,
PharmPK Discussion List Archive Index page
Copyright 1995-2010 David W. A. Bourne (david@boomer.org)